The fund was established last year and has 45 million euros at its disposal. It plans to invest the funds over five years in about 20 scientific startups, in cooperation with the i&i Prague incubator and the Institute of Organic Chemistry and Biochemistry of the CAS.
Kamila joined i&i Prague in May and has over a decade of experience in molecular biology, genome stability, and DNA repair, gained at the Institute of Molecular Genetics in Prague, the University of Oxford, and the University of Sussex.
The page says 700,000 people die worldwide each year from multidrug-resistant strains with no effective antibiotic; it says few new antibiotics are in development and major pharmaceutical companies have left the anti-infective field.
CasInvent Pharma is developing selective inhibitors of casein kinase 1 (CK1) enzymes, designed to target individual isoforms and selectively eradicate leukemic cells. The inhibitors have shown promising effects on hard-to-treat leukemias.
The company is an incubator focused on developing technology projects and start-ups in life sciences. It supports biotech projects in Central and Eastern Europe and collaborates with research institutions, start-ups, and international partners.
The company team draws on decades of experience from academic institutions, technology transfer, and industrial companies to develop biotech projects originating in academia and find commercial partners.
i&i Prague is a biotech incubator and venture builder in the heart of Europe. It aims to identify the potential of inventions in drug discovery, diagnostics, MedTech, and other life science fields.